US Bancorp’s MoonLake Immunotherapeutics MLTX Stock Holding History

US Bancorp’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.3K	Buy	2,323 +995	+75%	+$16.5K	﹤0.01%	2778
2025 Q4	$17.5K	Buy	1,328 +15	+1%	+$177	﹤0.01%	3131
2025 Q3	$9.41K	Sell	1,313 -1,436	-52%	-$74.8K	﹤0.01%	3332
2025 Q2	$130K	Buy	2,749 +541	+25%	+$22K	﹤0.01%	2301
2025 Q1	$86.3K	Buy	2,208 +1,178	+114%	+$50.8K	﹤0.01%	2456
2024 Q4	$55.8K	Buy	1,030 +161	+19%	+$8.22K	﹤0.01%	2681
2024 Q3	$43.8K	Buy	+869	New	+$40.7K	﹤0.01%	2800
2023 Q4	–	Sell	-3,547	Closed	-$202K	–	4084
2023 Q3	$202K	Buy	+3,547	New	+$196K	﹤0.01%	1822

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

US Bancorp's MLTX Position: Q1 2026 in Review

US Bancorp increased its MoonLake Immunotherapeutics (MLTX) stake by 75% in Q1 2026, buying an estimated $16.5K and bringing the position to 2,323 shares worth $43.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2778.

US Bancorp first reported a position in MLTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $202K in Q3 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

US Bancorp held 2,323 shares of MoonLake Immunotherapeutics worth $43.3K as of Q1 2026.
US Bancorp bought 995 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $16.5K.
MoonLake Immunotherapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #2778 holding.
US Bancorp first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 8 quarters since.
US Bancorp's MoonLake Immunotherapeutics position peaked at $202K in Q3 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.